| Identification | Back Directory | [Name]
(N-CROTONYL)-(4S)-ISOPROPYL-2-OXAZOLIDINONE | [CAS]
90719-30-5 | [Synonyms]
UIC-1005
Locostatin - UIC 1005
Locostatin >=98% (HPLC)
(R)-4-BENZYL-3-CROTONYL-2-OXAZOLIDINONE
(N-CROTONYL)-(4S)-BENZYL-2-OXAZOLIDINONE
(N-Crotonyl)-(R)-4-benzyl-2-oxazolidinone
4-but-2-enyl-3-propan-2-yl-2-oxazolidinone
(N-CROTONYL)-(4S)-ISOPROPYL-2-OXAZOLIDINONE
(S)-(+)-4-BENZYL-3-CROTONYL-2-OXAZOLIDINONE
(4S)-N-Crotonyl-4-benzyl-2-oxazolidinone,99%
(4S)-N-Crotonyl-4-benzyl-2-oxazolidinone, 99%
(4S)-3-[(E)-BUT-2-ENOYL]-4-BENZYL-2-OXAZOLIDINONE
(N-CROTONYL)-(4S)-ISOPROPYL-2-OXAZOLIDINONE USP/EP/BP
(4S)-4-benzyl-3-[(E)-but-2-enoyl]-1,3-oxazolidin-2-one
(4S)-3-[(E)-1-Oxo-2-butenyl]-4-(phenylmethyl)-2-oxazolidinone
2-Oxazolidinone, 3-[(2E)-1-oxo-2-buten-1-yl]-4-(phenylmethyl)-, (4S)- | [Molecular Formula]
C10H15NO3 | [MDL Number]
MFCD00075429 | [MOL File]
90719-30-5.mol | [Molecular Weight]
197.23 |
| Chemical Properties | Back Directory | [Melting point ]
84-88 °C(lit.)
| [Boiling point ]
351.0±25.0 °C(Predicted) | [density ]
1.205±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥30mg/mL | [form ]
powder | [pka]
-1?+-.0.40(Predicted) | [color ]
white to off-white | [InChI]
1S/C14H15NO3/c1-2-6-13(16)15-12(10-18-14(15)17)9-11-7-4-3-5-8-11/h2-8,12H,9-10H2,1H3/b6-2+/t12-/m0/s1 | [InChIKey]
UTZAFVPPWUIPBH-QSLRECBCSA-N | [SMILES]
C\C=C\C(=O)N1[C@H](COC1=O)Cc2ccccc2 |
| Hazard Information | Back Directory | [Uses]
Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice [1][2][3]. | [Biochem/physiol Actions]
Locostatin is a cell permeable, potent inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration. | [in vivo]
Locostatin (0.5 mg/kg; i.p.; once a day for 7 days) aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice[3]. | Animal Model: | 6 weeks, 18-22 g, male ICR mice (TAA model; injected intraperitoneally with 300 mg/kg TAA once a day for 2 days)[3] | | Dosage: | 0.5 mg/kg | | Administration: | I.p.; once a day for 7 days | | Result: | Decreased the expression of RKIP, led to more severe damage, such as steatosis and hepatic lesions, increased the production of ROS in the liver and TNF-α, IL-6 and IL-1β in the sera of mice with acute liver injury, inhibitd Nrf2 and HO-1 expression in the livers of mice, induced NF-κB activation in the livers of mice,increased the phosphorylation of JNK, p38 and ERK in liver tissues. |
| [References]
[1] Beshir AB, et al. Locostatin Disrupts Association of Raf Kinase Inhibitor Protein With Binding Proteins by Modifying a Conserved Histidine Residue in the Ligand-Binding Pocket. For Immunopathol Dis Therap. 2011;2(1):47-58. DOI:10.1615/forumimmundisther.v2.i1.60
[2] Mc Henry KT, et al. A non-antibacterial oxazolidinone derivative that inhibits epithelial cell sheet migration. Chembiochem. 2002 Nov 4;3(11):1105-11. DOI:10.1002/1439-7633(20021104)3:11<1105::AID-CBIC1105>3.0.CO;2-S
[3] Lin X, et al. Inhibition of RKIP aggravates thioacetamide-induced acute liver failure in mice. Exp Ther Med. 2018 Oct;16(4):2992-2998. DOI:10.3892/etm.2018.6542 |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|